[co-author: Vicky Vlontzou]
The European Medicines Agency (EMA) has announced that it now offers the possibility for simultaneous review of centralized marketing authorization applications (MAAs) and applications for a scientific opinion under Article 58 of Regulation (EC) 726/2004 on the authorization and supervision of medicinal products for human and veterinary use.
[View source.]